|
欢迎您加入月均活跃用户100万＋的科研社区！
如您有任何建议，请；有合作推广需求，请点此洽谈。 
|
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 已发表SCI？是时候来Springer出书了！ |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Expert Opinion On Drug Safety EXPERT OPIN DRUG SAF （此期刊被最新的JCR期刊SCIE收录） LetPub评分 6.5
56人评分
我要评分
声誉 7.7 影响力 5.3 速度 7.1 | |||||||||||||||||||||
| 期刊ISSN | 1474-0338 | 
蝌蝌APP，让您与同行交流更轻松
 立即下载 | ||||||||||||||||||||
| E-ISSN | 1744-764X | |||||||||||||||||||||
| 2024-2025最新影响因子 （数据来源于搜索引擎） | 3.1 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2025年10月27日：2.369 | |||||||||||||||||||||
| 2024-2025自引率 | 9.7%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 3.1 | |||||||||||||||||||||
| JCI期刊引文指标 | 0.63 | |||||||||||||||||||||
| h-index | 62 | |||||||||||||||||||||
| CiteScore （ 2025年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.tandfonline.com/loi/ieds20#.V48bfkz9cSQ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/eods | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting system Author: Zhang, Ying; Tong, Shuhua; Wan, Li Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2499219 Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS database Author: Zhang, Si-Han; Xu, Jin-Zhou; Zeng, Na; Xia, Zhi-Yu; Miao, Lin-Tao; Zhang, Ci; Wang, Shao-Gang; Xia, Qi-Dong Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2496434 Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases Author: Kan, Jingjing; Chen, Yechao; Gu, Qiaoling; Hu, Na; Qiao, Yanli; Chen, Yawen; Chen, Dayu; Zhang, Haixia Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2517232 Comprehensive post-marketing safety analysis of tildrakizumab: insights from the FDA adverse event reporting system Author: Zhao, Kaidi; Xiao, Shengxiang; Zhao, Yang; Tu, Chen Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2520422 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Expert Opinion On Drug Safety的语言要求，还能让Expert Opinion On Drug Safety编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Expert Opinion On Drug Safety编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ | |||||||||||||||||||||
| 出版商 | Taylor and Francis Ltd. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-药学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Bimonthly | |||||||||||||||||||||
| 出版年份 | 2002 | |||||||||||||||||||||
| 年文章数 | 282点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 6.28% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 82.27% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2024-2025年最新版） | WOS分区等级：2区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院期刊分区 （ 2025年3月最新升级版） | 点击查看中国科学院期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院期刊分区 （ 2023年12月升级版） |
| |||||||||||||||||||||
| 中国科学院期刊分区 （ 2022年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1474-0338%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 较慢,6-12周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Expert Opinion On Drug Safety顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting system Author: Zhang, Ying; Tong, Shuhua; Wan, Li Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2499219 PubMed DOI |
| 2. | Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS database Author: Zhang, Si-Han; Xu, Jin-Zhou; Zeng, Na; Xia, Zhi-Yu; Miao, Lin-Tao; Zhang, Ci; Wang, Shao-Gang; Xia, Qi-Dong Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2496434 PubMed DOI |
| 3. | Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases Author: Kan, Jingjing; Chen, Yechao; Gu, Qiaoling; Hu, Na; Qiao, Yanli; Chen, Yawen; Chen, Dayu; Zhang, Haixia Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2517232 PubMed DOI |
| 4. | Comprehensive post-marketing safety analysis of tildrakizumab: insights from the FDA adverse event reporting system Author: Zhao, Kaidi; Xiao, Shengxiang; Zhao, Yang; Tu, Chen Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2520422 PubMed DOI |
| 5. | Infection-related adverse events comparison of bortezomib, carfilzomib and ixazomib: a pharmacovigilance study based on FAERS Author: Xiang, Chenhuan; Guo, Rongrong; Ti, Juanjuan; Zhang, Shaoli; Wang, Tao Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2494692 PubMed DOI |
| 6. | Comparative safety analysis of baloxavir marboxil and oseltamivir based on the FAERS database Author: Tu, Yingqiu; Lai, Xin; Wan, Qing; Xu, Tiantian Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2495854 PubMed DOI |
| 7. | The safety analysis of lurasidone based on the real-world data of FAERS database Author: Luo, Ziyi; Zhang, Mengting; Liang, Weijian; Hu, Mianda; Jiang, Yunze; Lei, Xi; Wang, Zhenjie; Zhu, Jinfeng; Du, Yikuan; Liu, Yi; Yang, Chun Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2498054 PubMed DOI |
| 8. | Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system Author: Liang, Ting; Yan, Limei; Li, Junfeng; Gai, Dongzheng; Xu, Cong Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2499218 PubMed DOI |
| 9. | Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data Author: Ding, Lingqing; Chen, Congqin; Yang, Yongkuan; Xiao, Jie Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2500722 PubMed DOI |
| 10. | A real-world pharmacovigilance study and pharmacological analysis of sulfasalazine based on the FDA adverse event reporting system (FAERS) database Author: Guo, Dandan; Tang, Bufu; Luo, Peng; Zhang, Jian; Deng, Lvdan; Fu, Sentao; Shen, Zhijun; Li, Qing; Xie, Zhao; Hang, Na; Fan, Hongjie; Wang, Ling Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2488241 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| Springer发布AI审稿筛查工具：科研人怎么看？加入讨论 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共23条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
